Advertisement

Topics

Axsome's AXS-05 Helps Patients Quit Smoking Significantly in Phase II Trial

20:00 EDT 15 Apr 2019 | BioSpace

Axsome Therapeutics, based in New York City, announced that its AXS-05 met its primary endpoint for smoking cessation treatment. The drug significantly reduced daily smoking compared to patients on bupropion.

Original Article: Axsome's AXS-05 Helps Patients Quit Smoking Significantly in Phase II Trial

NEXT ARTICLE

More From BioPortfolio on "Axsome's AXS-05 Helps Patients Quit Smoking Significantly in Phase II Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...